NCT05270278View on ClinicalTrials.gov

Characteristics of Type 2- High Inflammatory Endotype of Asthma Using New Biomarkers From Peripheral Blood and Exhaled Air and Its Effect on the Outcome of Therapy

CompletedOBSERVATIONAL
Enrollment

89

Participants

Timeline

Start Date

August 16, 2022

Primary Completion Date

March 31, 2023

Study Completion Date

March 31, 2023

Conditions
Asthma; EosinophilicAsthma ChronicBronchial AsthmaAsthma, Bronchial
Trial Locations (1)

50005

Fakultní nemocnice Hradec Králové, Hradec Králové

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Value Outcomes Ltd.

OTHER

NCT05270278 - Characteristics of Type 2- High Inflammatory Endotype of Asthma Using New Biomarkers From Peripheral Blood and Exhaled Air and Its Effect on the Outcome of Therapy | Biotech Hunter | Biotech Hunter